Aktienanalyse zu Gyre Therapeutics Inc (GYRE)GYREGyre Therapeutics Inc

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Gyre Therapeutics is not a good buy right now due to significant financial challenges and poor technical indicators. The current price is $6.08, and the RSI is at a very low 18.42, indicating oversold conditions. Additionally, the stock has seen a 13.64% decline over the last five days and a staggering 27.10% drop over the past year, reflecting ongoing struggles. The main risk is the company's widening net loss, which reached $11.66 million in Q2 2026, a 472% increase from the previous year, raising concerns about its profitability and sustainability.